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Abstract
Owing to its rarity, rhabdomyosarcoma of the head and neck (HNRMS) has seldom been
discussed in the literature. As most of the data is based only on the retrospective experiences of
tertiary healthcare centers, there are difficulties in formulating a standard treatment protocol.
Moreover, the disease is poorly understood at its pathological, genetic, and molecular levels.
For instance, 20% of all histological assessment is inaccurate; even an experienced pathologist
can confuse rhabdomyosarcoma (RMS) with neuroblastoma, Ewing’s sarcoma, and lymphoma.
RMS can occur sporadically or in association with genetic syndromes associated with
predisposition to other cancers such as Li-Fraumeni syndrome and neurofibromatosis type 1
(von Recklinghausen disease). Such associations have a potential role in future gene therapies
but are yet to be fully confirmed. Currently, chemotherapies are ineffective in advanced or
metastatic disease and there is lack of targeted chemotherapy or biological therapy against
RMS. Also, reported uses of chemotherapy for RMS have not produced reasonable responses in
all cases. Despite numerous molecular and biological studies during the past three decades, the
chemotherapeutic regimen remains unchanged. This vincristine, actinomycin,
cyclophosphamide (VAC) regime, described in Kilman, et al. (1973) and Koop, et al. (1963), has
achieved limited success in controlling the progression of RMS. Thus, the pathogenesis of RMS
remains poorly understood despite extensive modern trials and more than 30 years of studies
exploring the chemotherapeutic options. This suggests a need to explore surgical options for
managing the disease. Surgery is the single most critical therapy for pediatric HNRMS.
However, very few studies have explored the surgical management of pediatric HNRMS and
there is no standard surgical protocol. The aim of this review is to explore and address such
issues in the hope of maximizing the number of options available for young patients with
HNRMS.
Categories: Pediatric Surgery, Plastic Surgery, Oncology
Keywords: rhabdomyosarcoma, soft tissue sarcoma, childhood, adolescence, head and neck,
parameningeal, skull base surgery, endoscopic, reconstruction, microsurgery
Introduction And Background
Rhabdomyosarcoma (RMS) is a rare high-grade soft tissue sarcoma of mesenchymal origin, with
evidence of striated muscle cell differentiation [1-7]. It represents 5%-7% of all pediatric
malignancies and is the most prevalent sarcoma of childhood and adolescence, i.e., 50% of all
reported sarcoma cases [1, 2, 4, 8-11]. It is also the third most common pediatric extracranial
solid tumor after neuroblastoma and Wilms’s tumor [2, 12-13].
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RMS lacks a capsule, a membranous envelope [8, 14-15]. This allows it to expand rapidly and
engulf regional structures, so there are early and considerable local invasions and significant
metastatic potential [2-4, 7, 9, 14, 16-18]. RMS also has a local relapse rate of 20%-40%, which
contributes to the dismal five-year survival rate of 24%-30% [1, 2, 8, 10, 12-16, 19]. Relapse
precedes rapid development of a metastatic disease [14]. Thus, diagnosis of RMS needs to be
timely, and a targeted therapeutic protocol should be initiated promptly for an optimal outcome
[18, 20-21]. However, this is seldom achieved; 50% of all RMS cases are high-grade, locally
advanced, or even metastatic at the time of diagnosis [22].
Most RMS in the pediatric population (30%-40%) occurs in the head and neck region [2-3, 8-11,
16-17, 23-24]. Between 1975 and 2005, there were significant and unexplained increases in the
annual incidences of rhabdomyosarcoma of the head and neck (HNRMS) by 1.16%, and of
alveolar RMS, mostly HNRMS, by 4.2% [16]. Pediatric HNRMS has an overall survival rate of
28.7% [16]. 44% percent of all HNRMS occurs in the parameningeal region: paranasal sinuses,
nasal cavity, nasopharynx, middle ear, and the skull base [8, 25-26].
Parameningeal location has the least favorable prognosis (Table 1) [8]. This is due to not only
the complexity of its anatomy and its proximity to the cranial cavity, and potential
dissemination via the cerebrospinal fluid (CSF), but also to the paucity of distinctive symptoms
(it can even be asymptomatic in early stages) (Table 2) [9, 20, 25]. Symptoms often mimic
chronic upper respiratory tract infection (URTI), otitis media (OM), and soft tissue injury (nasal
discharge and congestion, otorrhea, and mild swelling) [2]. Such characteristics of this location
increase the risk of misdiagnosis and of diagnosis delayed by up to a month [8-9, 18, 26-27].












Other (Trunk, Retroperitoneum, etc.)
TABLE 1: Pediatric RMS locations
RMS; Rhabdomyosarcoma
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Pediatric HNRMS Characteristics Description
Histology Lacks a Capsule [8, 14, 15]
Most Common Location Parameningeal [8, 25, 26]
Presentation Very few symptoms mimicking URTI, OM, and Soft-Tissue Injury[2]
Rate of Advanced Cancer at the Time of
Diagnosis 50% [22]
Misdiagnosis/Delayed Diagnosis Rate High [8, 9, 18, 26, 27]
Rate of Growth Rapidly Progressive [2, 4, 7, 9, 16]
Recurrence Rate 20% – 40% [8, 10, 12, 13, 16]
Five-year Survival Rate Post-recurrence 24% – 30% [1, 2, 8, 14-16, 19]
Metastatic Potential Rapidly Progress to Metastatic Disease Post-recurrence [14]
TABLE 2: Characteristics of pediatric HNRMS
HNRMS; rhabdomyosarcoma of the head and neck, URTI; upper respiratory tract infection, OM; otitis media
Surgery is the mainstay of managing parameningeal HNRMS [28]. However, surgical resection
is challenging owing to the high likelihood of a disease-positive margin post-resection and risk
of injury to the brain parenchyma because of its anatomical proximity and complexity [8, 22,
25-27]. Moreover, the role of surgery has been deemed limited in the pediatric population
because it is more difficult to achieve suitable surgical access, and functional and cosmetic
morbidities often follow [25-26]. However, innovations in craniofacial operation and
reconstruction techniques, as an element of the multimodal, multidisciplinary protocol
developed by the Intergroup RMS Study Group (IRSG) and Children’s Oncology Group (COG),
have yielded satisfactory results in recent years [25]. This protocol focuses mainly on non-
surgical interventions.
Review
Limitations of current chemotherapeutic and potential novel
biological therapy regimens
Intergroup RMS Study Group (IRSG) and Children’s Oncology Group (COG) previously
conducted clinical trials to assess the efficacy of adding agents such as doxorubicin, etoposide,
ifosfamide, and irinotecan to the vincristine, actinomycin, cyclophosphamide (VAC) regime,
and even attempted to increase the dose of cyclophosphamide in the hope of achieving better
prognoses [2, 29]. However, none of these endeavors led to a significant improvement [2, 29].
In recent years, extensive studies exploring potential novel molecular targets have been
conducted on animal models, including genetically-modified and xenograft models [5, 8, 30-
31]. These were followed by comprehensive clinical trials to assess the efficacies of insulin-like
growth factor (IGF1) receptor inhibitors such as cixutumumab
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(www.clinicaltrials.govNCT00831844); the vascular endothelial growth factor (VEGF) inhibitor
sorafenib (www.clinicaltrials.govNCT01502410); granulocyte-macrophage colony-stimulating
factor (GM-CSF) inhibitors such as sargramostim (www.clinicaltrials.govNCT00003955,
NCT00002995, NCT00003597,NCT00025363, NCT00003958); and epidermal growth factor
receptor (EGFR) inhibitors such as erlotinib [8]. Unfortunately, none of these trials
demonstrated the novel agents’ clinical efficacies and some were prematurely terminated owing
to patients’ inability to tolerate the protocol (Figure 1) [1, 5, 12, 30, 32]. The value of
chemotherapy and biological therapy in managing rhabdomyosarcoma (RMS) remains unclear
[31-32].
FIGURE 1: The chronology of chemotherapeutic and biological
regimens for pediatric RMS
RMS; rhabdomyosarcoma, VAC; vincristine/actinomycin/cyclophosphamide, IRSG; Intergroup
RMS Study Group, COG; Children's Oncology Group, NCI; National Cancer Institute
 
Current multi-modal, multi-disciplinary protocol for managing
RMS
The rarity of RMS and the poor understanding of its pathogenesis have encouraged
international research groups, i.e., IRSG and COG, to develop a stratification system to assess
prognosis and to formulate standardized therapeutic protocols to introduce more targeted
management [8].
Since the 1970s, using extensive analyses of clinical data, IRSG has developed a
multidisciplinary stratification system that categorizes RMS into Group I (a localized disease
that is completely resected) to IV (metastatic disease) [5, 8, 30, 31]. This system has allowed
highly individualized multimodal therapeutic protocols, i.e., combinations of surgery,
radiotherapy, and chemotherapy [5, 8, 16, 20, 26], to be integrated into RMS management and
has contributed to the increase in five-year survival rate from 25% in 1970 to 87% [2, 3, 5, 8, 14,
16, 17, 30]. However, the 87% relates to a patient group with confined, favorable location [9, 12].
It is necessary to explore the efficacy of such protocols in groups with unfavorable factors (five-
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year survival rate of 31%) i.e., parameningeal location, alveolar histology, >10 years of age,
incomplete surgical resection prior to adjuvant systemic treatment, and regional lymph node
infiltration [8, 18, 22, 30]. The IRSG/COG clinical grouping system is depicted in Table 3. The
clinical groups are assigned at diagnosis, i.e., after initial surgical management aimed at
achieving wide local excision with a disease-negative margin and providing the most accurate
prediction of treatment prognosis [31]; “operability” is the single most significant influence on
patient survival (Table 3) [15].
Group Definition Survival rate
I Completely resected localized tumor 87%
IIA Grossly resected tumor WITH microscopic residual disease ≤ 31%
IIB Completely resected involved regional nodes with NO microscopic residual disease 31% – 87%
IIC Grossly resected involved regional nodes WITH microscopic residual disease ≤ 31%
III Incompletely resected tumor WITH gross residual disease OR biopsy-only ≤ 31%
IV Distant metastasis 0%
TABLE 3: COG/IRSG clinical group stratification system for RMS
RMS; rhabdomyosarcoma, COG; Children's Oncology Group, IRSG; Intergroup RMS Study Group
Challenges of approaching HNRMS surgically:
Surgical management of parameningeal HNRMS: conservative
or revolutionary
From reviewing numerous articles, we concluded that there are two conflicting views amongst
surgeons on the surgical management of parameningeal HNRMS: the conservative and the
revolutionary. 
Conservative
The traditional surgical intervention for RMS has been extensive, wide local resection with
concomitant removal of a 0.5 cm thick envelope of normal tissue to achieve a clear disease-
negative margin and to preserve the functions of nearby vital structures [10, 15, 31]. The aim of
RMS surgery has been to perform a “curative,” complete resection to achieve the 80% overall
survival rate [2, 6, 10]. However, it is often not possible to achieve such a margin in a complex
anatomy such as that of the parameningeal region.
Resection of tumors in the head and neck region is especially challenging because of important
tissues nearby such as neurovascular bundles and the brain, the complexity of the anatomy, and
spatial restraints [14, 15, 19, 20, 28, 33]. Therefore, it is difficult to perform an ideal wide en
bloc resection with a disease-negative margin without injuring adjacent structures [14, 15, 19,
20, 28, 33] and risking postoperative morbidities such as problems with vocalization, food
ingestion, and respiration, and also serious cosmetic defects [14, 15, 19, 20, 28, 33].
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Hence, a number of authors encourage abandonment of the surgical approach, except for
excisional biopsy [8, 31], if the lesion is situated deep in the head and neck or if adequate
surgical access is not attainable [8, 14], so functional and cosmetic defects that could affect
quality of life adversely are avoided [34]. They also discourage the use of surgical debulking in
the head and neck area [2, 29]. In addition, the COG recommends systemic therapy only for
high-grade, locally advanced, relapsed, or metastatic disease [2, 29]. Patients undergoing
resection of parameningeal HNRMS tend to be high-grade with a disease-positive margin [22].
As previously discussed, the grade is an important determinant of prognosis in RMS cases [22].
Revolutionary
In contrast, some authors advocate the use of challenging yet highly technical surgical
procedures to achieve a disease-negative margin for parameningeal tumors and to accomplish
“operability” by adopting a “surgical approach that is based on the individual characteristics of
each patient” [26]. They endorse combined craniofacial and endoscopic resection and
reconstructive surgery by a multidisciplinary team of laryngologists, maxillofacial surgeons,
neurosurgeons, plastic surgeons, and ophthalmologists [8, 27], and further stretch their support
of surgery to “palliative” operations.
Current surgical techniques for pediatric parameningeal
HNRMS
Current surgical interventions for pediatric parameningeal HNRMS include wide local excision
and endoscopic technology to achieve a disease-negative margin, reconstructive surgery
including that for skull base defects, and application of micro-surgery. The aim is relapse-free
remission of the disease and also a symptomatic relief for those undergoing chemotherapy and
the terminally ill, ultimately improving the quality of life of the young population. The
combination of technological advances and deep understanding of micro-anatomy of the head
and neck allows for a safe operation [33].
Traditional wide local resection to achieve a disease-negative
margin
This technique, when used in the head and neck area, can entail a risk of incomplete resection
[13]. Residual disease places RMS in a high-grade category, i.e., Group II to IV [34]. Half of all
high-grade tumors are followed by local recurrence and subsequent rapid progression into
metastasis [13]. Thus, the surgeon should aim for a good 0.5 cm margin in the first procedure if
possible [13]. Otherwise, second-look explorations may be necessary, especially if a gross
residual mass remains unresected [14, 15, 18, 20, 31].
Furthermore, a complete wide local resection of parameningeal HNRMS with a disease-
negative margin is often possible. For instance, Demonte, et al. describe a case of a 9.5-year-
old boy with relapsed maxillary sinus RMS who underwent wide local resection with
osteotomies, i.e., maxillectomy, mandibulectomy, and removal of the middle cranial fossa, and
had complete remission of the disease [35].
On the other hand, Lindford, et al. claim that a disease-positive margin does not diminish
survival rates in pediatric HNRMS if peri-operative chemoradiotherapies are performed [15]. In
addition, the recurrence risk plummets with the use of systemic adjuvant therapy, which is
recommended for all high-grade RMS [14, 30]. The prognosis is even more favorable if a second-
look excision is performed and is followed by adjuvant systemic therapy [26, 31]. This surgical
technique is referred to as “reasonable” excision, which “seems to be the best method of
initiating therapy” for RMS [10] and yields a survival rate comparable to that of radical
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resection [2, 10].
Minimally invasive endoscopic resection (MIER) as an
emerging surgical technique for HNRMS
Since the 1960s, craniofacial resection has been the surgical method of choice since it allows
wide excision with a satisfactory margin [36]. However, the method commonly led to major
functional and cosmetic morbidities [36], the most common functional defect being
cerebrospinal fluid (CSF) leakage in up to 20% of all cases [36]. In contrast, MIER minimizes
handling of the skull base and prevents the morbidity and further complications that
conventional resection delivers, i.e., meningitis, cerebral abscess, pneumocephalus, brain
herniation and, consequently, even death [36]. This reduction in morbidity not only improves
quality of life, it also shortens the period of hospital stay and reduces healthcare costs [36-37].
MIER provides such benefits by using a microscope, which provides magnified vision, better
lighting, and superior corner visualization, allowing vital structures to be identified in detail
and hence ensuring their preservation [27, 36]. MIER allows for ideal exposure of the median
and paramedian structures of the skull base including the cavernous sinus, once called “No
Man’s Land” [27, 37]. Tumors invading the cavernous sinus have traditionally been resected
radically via maxillectomy, the transcranial approach, and the petrosal approach; however, the
resection can now be done endoscopically [37].
He, et al. support the view that MIER is superior to conventional craniofacial resection in
reducing recurrence rate and improving overall survival in carefully-selected parameningeal
HNRMS cases [36, 38]. Their study also reported that only three out of 120 enrolled patients
showed post-operative complications, which were conservatively treated [36]. It also describes a
case of a locally advanced ethmoid sinus RMS invading the skull base, which was successfully
cured by MIER [36]. In addition, Bostanci, et al. report another case of parameningeal RMS in a
two-year-old, which was completely resected by MIER with a margin free of disease [18].
MIER also allows chemotherapy to be resumed immediately postoperatively [28]. When MIER
was combined with perioperative chemoradiotherapies, the recurrence rate was lower and the
outcome was better than those of conventional surgery [26]. Moreover, the technology has a
major role in skull base reconstruction for repairing CSF leaks with fibrin glue, hydroxyapatite
cement, or autografts [15, 35, 39, 40]. The summary of the comparison between the traditional
wide local resection and MIER is summarized in Table 4.
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 Wide Local Resection Minimally Invasive Endoscopic Resection
Disease Negative Margin Achievability Satisfactory [13] Satisfactory [36]
Tissue Preservation Inferior [27, 36] Superior [27, 36]
Chemotherapy Resumption Delayed [28] Immediate [28]
Functional and Cosmetic Morbidities More [36] Fewer [36]
Overall Quality of Life Inferior [36] Superior [36]
Length of Hospital Stay Longer [36, 37] Shorter [36, 37]
Healthcare Cost More [36, 37] Less [36, 37]
Application in Skull Base Surgery No Yes [15, 35, 39, 40]
TABLE 4: Comparison of traditional wide local resection and minimally invasive
endoscopic resection in HNRMS
HNRMS; rhabdomyosarcoma of the head and neck
Reconstructive surgery as an adjunct to a radical resection to
minimize structural defects
Regardless of the method, i.e., conventional wide local resection, MIER, or a combination of
both, radical resection should be followed by reconstruction to restore significant functional
and anatomical defects using tissue flaps: regional or free [8, 30].
Reconstruction of a defect is especially crucial in pediatric patients since they are more
vulnerable to psychological trauma and are exposed to a lifetime risk of morbidities [1].
However, a reconstructive operation is especially difficult to perform for them since they are in
a growth phase and therefore susceptible to retraction deformity and severe post-
reconstruction donor site morbidity [41].
Flaps used in pediatric head and neck reconstructive surgery
It has been reported that pediatric patients are at greater risk of developing post-operative
complications with free flap use [41]. Hence, regional flaps are recommended whenever
feasible. However, the use of free flaps becomes inevitable when larger defects are repaired [15].
Weizman, et al. describe such flaps as effective and safe for HNRMS patients who have
undergone a radical operation [15, 28, 39]. In addition, free flaps show superior healing,
functional revitalization, and esthetic outcome (Table 5) [39]. For example, Ueda, et al. reported
a case of a 14-year-old girl whose big skin defect post-HNRMS-resection was reconstructed
with a free latissimus dorsi muscle flap, after which she was able to eat normally at week 12 and
remained disease-free at year four with a reported good quality of life [42].
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 Regional Flaps Free Flaps
Postoperative Complications Fewer [41] More [41]
Defect coverage Covers Small Defects [15] Covers Large Defects [15]
Healing Quality Inferior [39] Superior [39]
Cosmetic Outcome Inferior [39] Superior [39]
Functional Restoration Inferior [39] Superior [39]
TABLE 5: Comparison of regional and free flaps for use in pediatric HNRMS
HNRMS; rhabdomyosarcoma of the head and neck
Some examples of free flaps include: small bowel and forearm flaps for defects of moving parts
of the head [15-16, 37, 39, 43], scapular, lateral brachial, and latissimus dorsi flaps for deep soft
tissue defects [15, 16, 39, 43], and iliac crest, fibular, and scapular flaps for maxillary and
mandibular defects. Furthermore, repair of large maxillo-facial defects can be augmented with
an implantable prosthesis for optimal outcome [39].
However, restoration of bony defects is not always an option for pediatric patients since the
autograft can halt the growth of the recipient bone [42]. Moreover, Yano, et al. suggest that
osteotomies of the maxilla and mandible cause little disruption to overall facial bone
development [41]. Hence, bony reconstruction is ideally performed on adults. For instance,
Korfage, et al. presented a case of a 12-year-old who was successfully cured of parameningeal
RMS, after extensive debulking combined with postoperative chemotherapy [44]. The treatment
had resulted in mid-facial hypoplasia from abnormal bone growth [44]. The defect improved
significantly with rostral advancement of the mid-face by 1.5 cm over a month by an external
distraction frame (ID: lens.org/114-884-051-888-872) in combination with prosthodontics,
reconstruction of the palate with temporalis muscle, and rehabilitation [44].
A novel reconstruction technique: use of a perforator-based
flap
In the perforator-based flap technique, terminal cutaneous branches, which are thinly encircled
with only small amounts of fat and muscle, are salvaged from the donor site [43]. This thin flap
is transplanted to cover flat defects, which are very common in the oral mucosa or facial skin,
and produces an optimal esthetic outcome [43].
The importance of skull base reconstruction and its current
advances
Skull base defects are common sequelae of resection for parameningeal RMS [36]. Prompt
reconstruction is required to prevent associated complications and mortality [45]. Such
reconstruction is relevant to almost all patients who have undergone excision of high-grade
parameningeal HNRMS [35, 46]. Regional or free flaps are used to carry out this procedure
safely [35]. For instance, the temporalis muscle can be used in skull base surgery for patients
with parameningeal HNRMS and gives a satisfactory result [45]. Moreover, Gil, et al. conducted
a study across multiple healthcare institutions and discovered that most complications in
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pediatric skull base reconstruction were associated only with local wound healing [40].
Hayashi, et al. introduced an interesting technique of using the peri-fascial alveolar tissue
(which is highly flexible), claimed from the inguinal or femoral region, for complication-free
repairs of the skull base [47]. Only one patient out of 14 enrolled, i.e., 4.8%, had a further CSF
leak [40, 47].
The novel concept of palliative surgery and its potential
importance in HNRMS patient care
Very few papers discuss the importance of palliative surgery. Although locally advanced and
metastatic diseases may not have a surgical "cure," surgical "palliation" is certainly valuable
since patients with local recurrence or distant metastasis often survive up to 72 months [45].
For example, Weizman, et al. performed palliative surgery on a child with a relapsed local
disease and another with a metastatic disease, who both benefited from functional restoration
and improved quality of life [39]. Cantu, et al. added a study of multiple cases in which surgical
debulking of a skull base tumor provided significant symptomatic relief and a favorable quality
of life regardless of grade [45].
Although the COG recommends that high-grade tumors should be dealt with conservatively, it
is important to discuss the option of palliative surgery with the patient and parents to prolong
the disease-free time [27, 45, 48].
Discussion
Traditionally, resection with a clear margin followed by immediate reconstruction has been the
key to surgical management of RMS [15]. However, HNRMS poses a great technical challenge to
favorable resection [14, 15, 19, 20, 28, 33]. Although it is very challenging, recent advances in
surgical techniques and the better understanding of microanatomy now enable surgeons to
conduct operations beyond what was previously considered possible, i.e., surgical exploration
of the parameningeal area (Figure 2).
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FIGURE 2: A summary of surgical interventions for pediatric
HNRMS
HNRMS; rhabdomyosarcoma of the head and neck, MIER; minimally invasive endoscopic
resection
For the past three decades, despite a significant improvement in five-year survival rate from
25% to 87%, which was achieved by implementing IRSG/COG protocols in RMS management,
locally advanced, relapsed, and metastatic diseases are still considered difficult to treat in the
field of head and neck oncology [8, 22].
Researchers have struggled to discover and translate novel biological targets into targeted
therapies for RMS [1, 5, 12, 30, 32]. Moreover, VAC has been the constant chemotherapeutic
regime since the 1960s [1, 2, 12]. Interestingly, most clinical trials for RMS have focused on
understanding the genetics and biological pathogenesis of RMS and testing novel treatments,
but very few studies have focused on improving surgical options for HNRMS [5, 8, 30, 31]. This
uneven distribution of interests could have been aggravated by “the real breakthrough” [8]
during the 1960s when the first chemotherapeutics improved the survival rate from 5%-9%
(prior to 1969) to 25% in the 1970s; arguably the first and most significant achievement in the
history of RMS treatment [2, 3, 5, 8, 14, 16-17, 30].
Currently, although “operability” is the single most important assessment tool for survival in
RMS, there is a lack of and need for a standardized surgical protocol for HNRMS, which should
cover the use of endoscopic technology, reconstructive microsurgery, and palliative surgery.
Development of this protocol would further clarify surgery's critical role in improving the
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patient’s quality of life [36].
There is still a need for larger cohort studies comparing the efficacies of endoscopic and non-
endoscopic approaches in achieving a disease-negative margin in HNRMS, developing and/or
deploying novel surgical techniques, assessing prosthetic implants, rehabilitation devices for
HNRMS, and further exploring the novel reconstruction techniques, e.g., the perforator-based
flap technique described by Hölzle, et al. [39, 43].
A standardized surgical protocol for HNRMS and the potential study topics described above
would also be applicable to managing non-RMS tumors of the head and neck such as Ewing's
sarcoma, neuroblastoma, and squamous cell carcinoma [32, 36, 38, 46, 49]. Moreover, advances
in head and neck reconstruction technology would be useful in managing traumatic facial
injury such as loss of tissue and repairing burns wounds [43].
Conclusions
This study comprehensively reviews currently available surgical techniques and options for
advanced pediatric parameningeal HNRMS. Although surgery is often the most important
element in managing this disease, it is also the most challenging. We highlight the need for a
surgical protocol, which addresses all currently available surgical options, and large cohort
studies to explore novel surgical intervention for this disease. Such an effort would aid in
providing the most individualized interventions to patients. It would also help dispense
sufficient information about surgical risks and how they could be minimized and prevented,
with the use of modern technologies and available clinical data, to parents and older
patients. Most importantly, the procedure must be performed in the best interest of the patient
and parents, not for indulging in one’s egoism. The goal is to provide children and adolescents
with improved quality of life and minimized treatment-associated adverse events, which can
seriously affect one’s remaining decades of life.
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